(Reuters) – Pharmaceutical group GlaxoSmithKline Plc (GSK.L) is said to be in discussions with chipmaker Qualcomm Inc (QCOM.O) to form a joint venture as GSK looks for ways to develop medical technology, Bloomberg reported on Wednesday.
The talks are at an initial stage and nothing has been decided, people familiar with matter told Bloomberg. (bloom.bg/1UbZkSK)
GSK declined to comment, while Qualcomm was not immediately available for comments.
Earlier this month, Qualcomm said it was collaborating with Novartis AG (NOVN.VX) (NVS.N) to develop an inhaler for patients suffering from chronic obstructive pulmonary disease.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
